TC BioPharm (Holdings) plc Warrants
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat … Read more
TC BioPharm (Holdings) plc Warrants (TCBPW) - Total Assets
Latest total assets as of September 2024: $6.87 Million USD
Based on the latest financial reports, TC BioPharm (Holdings) plc Warrants (TCBPW) holds total assets worth $6.87 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TC BioPharm (Holdings) plc Warrants - Total Assets Trend (2019–2023)
This chart illustrates how TC BioPharm (Holdings) plc Warrants’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TC BioPharm (Holdings) plc Warrants - Asset Composition Analysis
Current Asset Composition (December 2023)
TC BioPharm (Holdings) plc Warrants's total assets of $6.87 Million consist of 63.8% current assets and 36.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.6% |
| Accounts Receivable | $1.23 Million | 13.8% |
| Inventory | $-1.23 Million | -13.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $615.17K | 6.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how TC BioPharm (Holdings) plc Warrants's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TC BioPharm (Holdings) plc Warrants's current assets represent 63.8% of total assets in 2023, an increase from 41.6% in 2019.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2023, up from 9.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 3.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 13.8% of total assets.
TC BioPharm (Holdings) plc Warrants Competitors by Total Assets
Key competitors of TC BioPharm (Holdings) plc Warrants based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
TC BioPharm (Holdings) plc Warrants - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TC BioPharm (Holdings) plc Warrants generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TC BioPharm (Holdings) plc Warrants is currently not profitable relative to its asset base.
TC BioPharm (Holdings) plc Warrants - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.20 | 0.53 |
| Quick Ratio | 1.12 | 1.61 | 0.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $423.86K | $ 950.33K | $ -1.97 Million |
TC BioPharm (Holdings) plc Warrants - Advanced Valuation Insights
This section examines the relationship between TC BioPharm (Holdings) plc Warrants's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -20.9% |
| Total Assets | $8.93 Million |
| Market Capitalization | $593.22K USD |
Valuation Analysis
Below Book Valuation: The market values TC BioPharm (Holdings) plc Warrants's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TC BioPharm (Holdings) plc Warrants's assets decreased by 20.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TC BioPharm (Holdings) plc Warrants (2019–2023)
The table below shows the annual total assets of TC BioPharm (Holdings) plc Warrants from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $8.93 Million | -20.90% |
| 2022-12-31 | $11.29 Million | +40.73% |
| 2021-12-31 | $8.02 Million | +10.42% |
| 2020-12-31 | $7.27 Million | -28.34% |
| 2019-12-31 | $10.14 Million | -- |